Erysipelotrichaceae

Erysipelotrichaceae is a family within the phylum Firmicutes that has drawn increasing attention for its consistent enrichment in metabolic disorders. Members of this family are Gram-positive, obligate anaerobes found throughout the mammalian gastrointestinal tract, where they participate in lipid and cholesterol metabolism.

Multiple studies have identified Erysipelotrichaceae enrichment as a recurring feature of obesity and metabolic syndrome. Mendelian randomization analyses have linked elevated abundance of this family to altered lipid profiles, including higher LDL cholesterol and triglycerides ([1], Mendelian randomization). The family is also enriched in cardiovascular disease states, where its abundance correlates with pro-atherogenic metabolic pathways ([2], cross-sectional; [3], review). Notably, Erysipelotrichaceae shifts have been observed in autoimmune thyroid conditions alongside other metabolic disruptions ([4], cross-sectional), suggesting the family may serve as a broader marker of host metabolic dysregulation rather than a pathogen in any single disease.

Cross-References

References (4)

  1. Da Teng, Wenjuan Jia, Wenlong Wang et al. (2024). Causality of the gut microbiome and atherosclerosis-related lipids: a bidirectional Mendelian Randomization study. BMC Cardiovascular Disorders. doi:10.1186/s12872-024-03804-3
  2. Junwen Zhu, Jin Lyu, Ruochi Zhao et al. (2023). Gut macrobiotic and its metabolic pathways modulate cardiovascular disease. Frontiers in Microbiology. doi:10.3389/fmicb.2023.1272479
  3. Md. Mominur Rahman, Fahadul Islam, Md. Harun-Or-Rashid et al. (2022). The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation. Frontiers in Cellular and Infection Microbiology. doi:10.3389/fcimb.2022.903570
  4. Zhao H, Yuan L, Zhu D et al. (2022). Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis. Polish Journal of Microbiology. doi:10.33073/pjm-2022-016

Related Articles